Celcuity LLC (CELC)

Currency in USD
87.32
-0.92(-1.04%)
Closed·
87.99+0.67(+0.77%)
·
CELC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
86.9189.51
52 wk Range
11.28151.02
Key Statistics
Prev. Close
88.24
Open
88.54
Day's Range
86.91-89.51
52 wk Range
11.28-151.02
Volume
808.92K
Average Volume (3m)
1.22M
1-Year Change
600.8026%
Book Value / Share
1.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CELC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
161.09
Upside
+84.48%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Celcuity LLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 161.09
(+84.48% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy171.00+95.83%189.00MaintainJun 03, 2026
H.C. Wainwright
Buy145.00+66.06%185.00MaintainJun 03, 2026
Guggenheim
Buy165.00+88.96%-MaintainJun 03, 2026
Wells Fargo
Buy166.00+90.11%183.00MaintainJun 03, 2026
Citizens
Buy160.00+83.23%-MaintainJun 03, 2026

Celcuity LLC Earnings Call Summary for Q1/2026

  • Celcuity reported Q1 2026 EPS of -$0.97, beating analyst estimates of -$1.04 by 6.73%; stock rose 0.82% in aftermarket trading to $125.49.
  • Net loss widened to $46.8M from $34.7M year-over-year; company maintains strong cash position of $387.1M to fund operations through 2027.
  • Lead drug candidate gedatolisib showed promising clinical trial results for HR-positive, HER2-negative advanced breast cancer treatment.
  • Management expressed confidence in meeting operational milestones despite high cash burn rate and increased administrative expenses.
  • Stock delivered 1,141% return over past year, though InvestingPro analysis suggests current valuation appears overvalued at 59.83x Price/Book.
Last Updated: 2026/05/14, 23:40
Read Full Transcript

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0,97 / -1,04
Revenue / Forecast
-- / 4,7M
EPS Revisions
Last 90 days

CELC Income Statement

Compare CELC to Peers and Sector

Metrics to compare
CELC
Peers
Sector
Relationship
P/E Ratio
−22.3x−1.2x−0.5x
PEG Ratio
0.80−0.020.00
Price/Book
80.5x2.7x2.6x
Price / LTM Sales
-5.7x3.0x
Upside (Analyst Target)
89.0%198.8%58.6%
Fair Value Upside
Unlock8.4%10.2%Unlock

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
9,93M20,37%876,54M
Other Institutional Investors
52,71M79,63%4,65B
Public Companies & Retail Investors
0,000,00%0,00
Total
62,64M100,00%5,53B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Baker Bros. Advisors LP16,23%7 915 792698 489
Baker Brothers Life Sciences, L.P.14,79%7 211 484636 341

FAQ

What Is the Celcuity (CELC) Stock Price Today?

The Celcuity stock price today is 87,32 USD.

What Stock Exchange Does Celcuity Trade On?

Celcuity is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Celcuity?

The stock symbol for Celcuity is "CELC."

What Is the Celcuity Market Cap?

As of today, Celcuity market cap is 4,30B USD.

What Is Celcuity's Earnings Per Share (TTM)?

The Celcuity EPS (TTM) is -3,89.

When Is the Next Celcuity Earnings Date?

Celcuity will release its next earnings report on Aug 06, 2026.

From a Technical Analysis Perspective, Is CELC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Celcuity Stock Split?

Celcuity has split 0 times.

How Many Employees Does Celcuity Have?

Celcuity has 155 employees.

What is the current trading status of Celcuity (CELC)?

As of Jun 16, 2026, Celcuity (CELC) is trading at a price of 87,32 USD, with a previous close of 88,24 USD. The stock has fluctuated within a day range of 86,91 USD to 89,51 USD, while its 52-week range spans from 11,28 USD to 151,02 USD.

What Is Celcuity (CELC) Price Target According to Analysts?

The average 12-month price target for Celcuity is 161,09 USD, with a high estimate of 175 USD and a low estimate of 145 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +84,48% Upside potential.

What Is the CELC Premarket Price?

CELC's last pre-market stock price is 87,56 USD. The pre-market share volume is 540,00, and the stock has decreased by -0,68, or -0,77%.

What Is the CELC After Hours Price?

CELC's last after hours stock price is 87,99 USD, the stock has decreased by 0,67, or 0,77%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.